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Objectives: The aim of this study was to describe clinical and virological outcomes in therapy-naive
HIV-1-positive patients treated in a routine ART programme in rural Cameroon.
Methods: In a prospective cohort, 300 consecutive patients starting first-line ART were enrolled and followed for
12 months. Among 238 patients with available viral load data at Month 12, logistic regression was used to ana-
lyse risk factors for virological failure (≥1000 HIV RNA copies/mL) including clinical, immunological and virological
parameters, as well as data on drug adherence. Population sequencing was performed to detect the presence of
drug-resistance mutations in patients with virological failure at Month 12; minority drug-resistancemutations at
baseline were analysed using next-generation sequencing in these patients and matched controls.
Results: At Month 12, 38/238 (16%) patients experienced virological failure (≥1000 HIV RNA copies/mL). Patients
with virological failure were younger, had lower CD4 cell counts and were more often WHO stage 3 or 4 at base-
line. Sixty-three percent of patients with virological failure developed at least one drug-resistance mutation. The
M184V (n¼18) and K103N (n¼10)mutations weremost common. At baseline, 6/30 patients (20%) experiencing
virological failure and 6/35 (17%) matched controls had evidence of minority drug-resistance mutations using
next-generation sequencing (P¼0.77). Lower CD4 count at baseline (OR per 100 cells/mm3 lower 1.41, 95% CI
1.02–1.96, P¼0.04) and poorer adherence (OR per 1% lower 1.05, 95% CI 1.02–1.08, P,0.001) were associated
with a higher risk of virological failure. Unavailability of ARTat the treatment centre was the single most common
cause for incomplete adherence.
Conclusions: Virological failure after 1 year of ART was not associated with minority drug resistance at baseline
but with incomplete adherence. Strategies to assure adherence and uninterrupted drug supplies are pivotal fac-
tors for therapy success.
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Introduction
The scaling up of antiretroviral treatment programmes in
sub-Saharan Africa has led to favourable results.1,2 However,
poor retention in care,3 inadequate adherence to treatment and
lack of stock of antiretroviral drugs among others have been iden-
tified as factors contributing to adverse outcomes of ARTand the
development of drug resistance.3,4 Furthermore, it has been
shown that up to 7.4% of antiretroviral-naive patients harbour a
primary drug-resistant virus, although data from central Africa are
scarce.5 In the present prospective cohort study, we aimed to
assess the prevalence and determinants of virological failure,
including primary drug resistance, in HIV-infected patients in
Cameroon.
Methods
In the outpatient HIV clinic of the Bamenda Regional Hospital, patients
were assessed for ART eligibility according to national guidelines and
WHO recommendations.6 At the time of the study, two doctors together
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with pharmacists and social workers were attending to a total of 4500 HIV
patients andmore than 30 new patients every month. Ethical approval for
the performance of the study was granted by the National Ethics
Committee in Yaounde, Cameroon. Written informed consent was
obtained from all of the individuals.
From January 2010 to October 2010, 300 consecutive patients being
initiated on first-line ART were included in the study. The sample size
was determined assuming a prevalence of antiretroviral resistance of
20%, a precision of 5% and a drop-out rate of 20%. Patients were moni-
tored every 3 months by a study physician. Every 6 months, an analysis of
blood count, liver function tests and CD4+ Tcell count was performed and
plasma was cryopreserved. The returned pills were counted and the
adherence ratiowas calculated as the numberof days a patientwas taking
the correct number of prescribed antiretroviral drugs divided by the num-
ber of days since the start of therapy.
Viral load testing was retrospectively performed using the Abbott real-
time HIV-1 amplification reagent kit (University of Bonn). Drug-resistance
testing in patients virologically failing at Month 12 by population sequen-
cing was performed using the Viroseq version 2 (Abbott) (University of
Zurich). The retrospective drug-resistance testing of baseline samples
by next-generation sequencing was performed using 454 pyrosequencing
technology as previously described7 (University of Zurich; see the
Supplementary data available at JAC Online for details) on patients
with virological failure at Month 12 and an equal number of patients
Table 1. Baseline characteristics of patients with available viral load (VL) data at Month 12 (n¼238)
Virological success
(VL ,1000 HIV RNA copies/mL, n¼200)
Virological failure
(VL ≥1000 HIV RNA copies/mL, n¼38) P
Gender, n (%) 0.07a
male 60 (30) 9 (24)
female 140 (70) 29 (76)
Education, n (%) 0.29a
none 6 (3) 1 (3)
primary 111 (56) 22 (58)
secondary 74 (37) 13 (34)
university/higher 9 (5) 2 (5)
History of TB, n (%) 0.10a
no 179 (90) 31 (82)
yes 21 (11) 6 (16)
Current TB, n (%) 0.12a
no 191 (96) 35 (92)
yes 9 (5) 2 (5)
WHO stage, n (%) 0.01a
1 94 (47) 12 (32)
2 50 (25) 10 (26)
3 40 (20) 9 (24)
4 15 (8) 5 (13)
NRTI backbone, n (%) 0.35a
ZDV/3TC 165 (83) 28 (74)
d4T/3TC 2 (1) 0 (0)
TDF/3TC 13 (7) 6 (16)
TDF/FTC 20 (10) 4 (11)
Third drug, n (%) 0.92a
ABC 1 (1) 0 (0)
EFV 49 (25) 10 (26)
LPV/r 9 (5) 1 (3)
NVP 141 (71) 27 (71)
Age (years), median (range) 37.8 (19.5–78.1) 34.9 (22.3–79.5) 0.03b
CD4+ T cells/mm3, median (range) 184 (1–889) 116 (3–349) 0.05b
VL (log10 HIV RNA copies/mL), median (range) 5.4 (2.3–6.7) 5.5 (3.3–6.4) 0.99
b
Haemoglobin (mg/dL), median (range) 11 (6.3–20.3) 10.7 (5.6–17) 0.54b
ZDV, zidovudine; 3TC, lamivudine; d4T, stavudine; TDF, tenofovir; FTC, emtricitabine; ABC, abacavir; EFV, efavirenz; LPV/r, lopinavir boosted with ritonavir;
NVP, nevirapine.
ax2 test.
bWilcoxon rank sum test.
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with a viral load ,1000 HIV RNA copies/mL at Month 12 who were
matched according to gender, age, CD4+ T cell count and viral load at
baseline.
The characteristics of patients with and without virological failure were
compared using the Wilcoxon rank sum test for continuous data and x2
tests for categorical data.
Risk factors were assessed by logistic regression models. All the tests
were two-sided and P,0.05 was considered significant. STATA v12 was
used for all analyses. One patient with HIVgroup O virus, which is naturally
resistant to NNRTI drugs, was excluded from the risk factor analysis.
Results
A total of 300 HIV-positive patients who started ART were
included from January 2010 to October 2010. Viral load testing
at Month 12 was successfully performed for 238 patients
(Figure S1) and these patients were included in the analyses.
Of these patients, 200 (84%) had a viral load of ,1000 HIV RNA
copies/mL, 160 (67%) patients had a viral load of ,50 HIV RNA
copies/mL and 38 (16%) patients experienced virological failure
(Table 1).
At least one HIV-1 drug-resistance mutation was detected in
27/38 (71%) patients with virological failure at Month 12 using
population sequencing. In 24 patients (63%), mutations asso-
ciated with high-level resistance to any of the prescribed drugs
were found. The M184V mutation was the most frequently
detected NRTI mutation (n¼18), the most commonly observed
NNRTI resistance mutations being K103N (n¼10), Y181C (n¼7)
and G190A (n¼6) (Table S1).
Drug-resistance mutations at baseline were detected in 6/30
patients (20%) experiencing virological failure and 6/35 (17%)
matched controls using next-generation sequencing (P¼0.77).
The most common mutations were V90I (n¼4) and V108I
(n¼3). The M184Vmutation was detected in one patient at a fre-
quency of 1.3% and the K103Nmutation was detected in another
patient at a frequency of 1.7%. Both patients had virological fail-
ure at Month 12, when neither the M184V nor the K103N muta-
tion was detected (Table S1).
In the multivariable logistic regression, a lower baseline CD4
cell count (OR per 100 cells/mm3 lower 1.47, 95% CI 1.02–2.08,
P¼0.04) and a lower adherence ratio (OR per 1% lower 1.04, 95%
CI 1.02–1.07, P,0.001) were associated with a higher risk of viro-
logical failure (Table 2). A higher age was associated with a higher
adherence ratio (P¼0.01) but not with lower virological failure
rates (P¼0.21). The most common reasons for incomplete drug
intake (adherence ratio ,95%) included ‘drugs were out of
stock’ (37%), ‘patient was out of town and could not collect
drugs in time’ (8%) and ‘discontinued drugs because of side
effects’ (8%).
Discussion
In this study in rural Cameroon, 67% of patients achieved a viral
load of ,50 HIV RNA copies/mL after 1 year of treatment. HIV-1
drug-resistance mutations were detected in 71% of patients with
virological failure. A previous study from the capital of Cameroon
reported an undetectable viral load in 49% of patients after
2 years of ART, with major drug mutations being detected in
only 10%.8 Being treated in a rural centre has previously been
shown to be a risk factor for virological failure in a study from
Gabon.9
Poorer adherence was clearly associated with a higher risk of
virological failure. Interestingly, younger patients (,36 years)
showed poorer adherence but similar rates of virological failure
and resistance compared with older patients. This supports previ-
ous findings that good adherence does not protect from the
development of drug resistance if the drugs are continued in the
absence of complete viral suppression.10
The predominant reasons for non-adherence were organiza-
tional; 41% of patients stated that their refill date was scheduled
on a public holiday or that the ART drugs were out of stock. This
suggests that repeated interruptions of drug supply and subse-
quent intake of antiretroviral drugs may be a specific problem in
rural Africa. Our results are in line with those from studies from
South Africa and Malawi suggesting that incomplete adherence
is associated with a higher risk of virological failure11 and that
patients with previous treatment interruptions have higher rates
of drug resistance.12
Using next-generation sequencingwith a detection limit of 1%,
we found primary drug-resistance mutations prior to ART initi-
ation in 20% of patients with later virological failure, and at a
Table 2. Univariable and multivariable logistic regression analysing risk factors for virological failure
Univariable logistic regression Multivariable logistic regression
OR 95% CI P.z OR 95% CI P.z
Female sex (versus male) 1.33 0.59–3 0.49
Age (per 10 years older) 0.71 0.49–1.02 0.07 0.79 0.54–1.15 0.21
CD4 baseline (per 100 cells/mm3 lower) 1.41 1.02–1.96 0.04 1.47 1.02–2.08 0.04
WHO Stage 3 or 4 (yes versus no) 1.96 0.95–4.02 0.07 1.38 0.61–3.11 0.43
Viral load at baseline (per 1 log10 HIV RNA copies/mL higher) 1.06 0.64–1.77 0.81
Efavirenz at baseline (yes versus no) 1.24 0.56–2.77 0.59
Nevirapine at baseline (yes versus no) 0.96 0.44–2.07 0.91
Current TB (yes versus no) 1.25 0.26–6.03 0.78
Haemoglobin at baseline (per 1 mg/dL higher) 0.91 0.76–1.09 0.33
Adherence ratio (per 1% lower)a 1.05 1.02–1.08 ,0.001 1.04 1.02–1.07 ,0.001
aFrom baseline to last clinical follow-up.
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similar frequency in matched controls without virological failure.
None of the mutations occurred at a frequency high enough to
be picked up by conventional population-based sequencing. A pre-
vious pooled analysis shows an association between the existence
of minority drug-resistance mutations and virological failure,13
but the clinical use of detecting minorities in longitudinal studies
seems, so far, to be limited.14–16 We found that acquired drug-
resistance mutations became detectable within the first year of
antiretroviral therapy in a substantial number of patients.
Because of cross-class resistance, future therapeutic options are
limited to drugs from other classes such as protease or integrase
inhibitors, which are not yet widely available in Africa.17
Our study had the limitation that follow-up was limited to
1 year and the number of patients with virological failure was lim-
ited. Minority variants were only assessed in a subset of patients
with virological failure and matched controls. However, our study
is among the very few to provide information on the existence of
minority variants in an African setting.
In conclusion, minority drug-resistance mutations were
detected by next-generation sequencing at baseline in a substan-
tial proportion of patients but were not associated with virological
failure after 1 year of first-line ART. An important reason for
incomplete adherence to ART, as a major determinant of the sub-
stantial virological failure rates in our study, was the unavailability
of drugs at the treatment centre. Strategies for an uninterrupted
supply chain to rural parts in Africa seem pivotal in order to
achieve sustainable treatment success.
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